These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19565187)

  • 1. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
    Wu J; Henderson C; Feun L; Van Veldhuizen P; Gold P; Zheng H; Ryan T; Blaszkowsky LS; Chen H; Costa M; Rosenzweig B; Nierodzik M; Hochster H; Muggia F; Abbadessa G; Lewis J; Zhu AX
    Invest New Drugs; 2010 Oct; 28(5):670-6. PubMed ID: 19565187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.
    Lin CC; Hsu C; Hsu CH; Hsu WL; Cheng AL; Yang CH
    Invest New Drugs; 2007 Feb; 25(1):77-84. PubMed ID: 16937079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
    Ogura M; Kim WS; Uchida T; Uike N; Suehiro Y; Ishizawa K; Nagai H; Nagahama F; Sonehara Y; Tobinai K
    Jpn J Clin Oncol; 2021 Feb; 51(2):218-227. PubMed ID: 33051668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
    Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
    Tsimberidou AM; Camacho LH; Verstovsek S; Ng C; Hong DS; Uehara CK; Gutierrez C; Daring S; Stevens J; Komarnitsky PB; Schwartz B; Kurzrock R
    Clin Cancer Res; 2009 Jul; 15(14):4769-76. PubMed ID: 19584162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
    Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
    Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].
    Qu FL; Hao XZ; Qin SK; Liu JW; Sui GJ; Chen Q; Qu T; Zhang HP; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):697-701. PubMed ID: 22340053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
    Goyal L; Supko JG; Berlin J; Blaszkowsky LS; Carpenter A; Heuman DM; Hilderbrand SL; Stuart KE; Cotler S; Senzer NN; Chan E; Berg CL; Clark JW; Hezel AF; Ryan DP; Zhu AX
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1305-14. PubMed ID: 24121453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
    Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS
    Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
    Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
    Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
    Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib in liver function impaired advanced hepatocellular carcinoma.
    Ji YX; Zhang ZF; Lan KT; Nie KK; Geng CX; Liu SC; Zhang L; Zhuang XJ; Zou X; Sun L; Zhang ZC
    Chin Med Sci J; 2014 Mar; 29(1):7-14. PubMed ID: 24698672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.